RxDoctor Payments Data

Nathan Petula, PA

Physician Assistant · Shippensburg, PANPI 1245363365

Payments from drug & device makers

$15,511in general payments, 2019–2025

Across 1,021 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$564
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$15,38199%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,511 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,414
Medicare patients
16
Services billed
31

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide154$168,965
JardianceEmpagliflozin155$148,460
EliquisApixaban109$93,126
MounjaroTirzepatide79$83,193
FarxigaDapagliflozin Propanediol51$38,202
Soliqua 100-33Insulin Glargine/Lixisenatide23$37,449
TrulicityDulaglutide23$29,374
RybelsusSemaglutide17$29,188
SynjardyEmpagliflozin/Metformin Hcl24$26,662
XareltoRivaroxaban27$26,158
Xigduo XrDapaglifloz Propaned/Metformin16$19,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$19,498
Tresiba Flextouch U-200Insulin Degludec12$12,986
GlyxambiEmpagliflozin/Linagliptin15$11,567
Trijardy XrEmpaglifloz/Linaglip/Metformin15$11,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Glyxambi, Trijardy Xr, Synjardy Xr$263$223,580249 claims
Novo NordiskOzempic, Rybelsus$3,347$198,153171 claims
Lilly USA, LLCMounjaro, Trulicity$1,065$112,567102 claims
PfizerEliquis$564$93,126109 claims
AstraZenecaFarxiga, Bevespi Aerosphere$1,283$43,72664 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$79$37,44923 claims
Johnson & JohnsonXarelto$236$26,15827 claims
GSKTrelegy Ellipta$550$19,49819 claims
AbbVieLinzess$1,487$9,48713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Shippensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →